Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk of cardiovascular disease, finds a study.
European guidelines on the prevention of CVD do not recommend aspirin for individuals free from CVD due to the increased risk of major bleeding.
This advice was subsequently supported by results in moderate risk patients, diabetic patients and in people over 70.
The primary finding from the study’s randomised trial was that in people aged 70 years or over with no known CVD, there was no effect of 100 mg of daily aspirin on the composite primary endpoint of disability-free survival.
This analysis examined whether the results for the primary endpoint of disability-free survival might vary by the baseline level of CVD risk.
“The findings emphasise that the risk-benefit trade-off for aspirin use in healthy older men and women varies across levels of cardiovascular risk, said Christopher Reid of Curtin University, Australia. (ANI)
